A 3.4 cm Renal Mass in a Patient With CKD 3b and Cardiac Comorbidity
A 70-year-old man has an incidental 3.4 cm left renal mass found on CT performed for flank pain. The mass is solid, exophytic, interpolar, abuts but does not invade the sinus fat, and enhances from 32 to 62 HU. His eGFR is 31 mL/min/1.73 m² and stable. He has type 2 diabetes, hypertension, a BMI of 35, and a prior myocardial infarction; he takes aspirin, which he has not stopped. He lives independently and is active. He asks whether he can "just watch it" and whether he needs a needle biopsy before deciding anything.
1. Frame the competing risks and rank the reasonable management options for this cT1a mass.
Read the worked answer
The first thing to establish is that the dominant competing risk is cardiovascular, not oncologic. For a cT1a mass, 5-year cancer-specific survival with treatment exceeds 95%, while his diabetes, hypertension, prior MI, and age put his non-cancer mortality risk far higher. That reframing is what justifies discussing more than one option.
Partial nephrectomy remains the oncologic reference standard for cT1a and is oncologically equivalent to radical nephrectomy for T1 tumors while preserving function. With a baseline eGFR of 31, though, he is at real risk of postoperative AKI and progression to stage 4 CKD - so the technical goal is zero-ischemia or minimal-clamp partial nephrectomy. Radical nephrectomy would likely push him into the 20s and should be avoided if partial is feasible.
Thermal ablation (cryoablation, radiofrequency, microwave) suits an exophytic, interpolar, ≤3–4 cm tumor away from the collecting system and ureter: lower morbidity, shorter recovery, but a local recurrence rate in the range of 5–10% requiring committed imaging follow-up.
Active surveillance is defensible given his comorbidity, provided he accepts serial imaging and that treatment remains available later.
Decide with multidisciplinary input and explicit patient preference.
2. Does he need a renal mass biopsy, and what would you do with a benign result?
Read the worked answer
Biopsy is indicated when the result would change what you do - and here it might, because ablation and surveillance are both on the table.
The relevant fact is that roughly 15–20% of solid masses under 4 cm are benign (oncocytoma, lipid-poor angiomyolipoma). Before committing a patient with eGFR 31 to an ablative or surveillance pathway, histology and grade are useful. Biopsy is also valuable if you suspect lymphoma or metastasis.
Its limits must be stated honestly: nondiagnostic rates of 10–20%, sampling error with respect to grade, and a small risk of bleeding. If he were a fit 50-year-old heading straight to partial nephrectomy, biopsy would rarely change management and could be skipped.
A benign biopsy result should not end follow-up. Sampling error means a benign core does not exclude a adjacent carcinoma, and oncocytoma and chromophobe RCC can be indistinguishable on core. The practical response is to continue surveillance imaging rather than discharge him, and to treat growth or new heterogeneity as a trigger to revisit resection.
3. He chooses active surveillance. Which findings would make you intervene, and how would you structure follow-up?
Read the worked answer
Average growth of small renal masses on surveillance is on the order of 0.3 cm per year, and many grow not at all - so a single interval measurement should not trigger treatment on its own.
Triggers to intervene:
- Growth to or beyond roughly 4 cm, where metastatic potential rises meaningfully.
- A growth rate above about 0.5 cm per year sustained across two intervals.
- New heterogeneity, nodularity, or invasion of sinus fat or vein.
- Patient preference change or new symptoms (hematuria, pain).
Follow-up structure:
- Contrast-enhanced abdominal imaging at about 3–6 months to establish the growth trajectory, then annually if stable.
- Chest imaging per institutional protocol for a mass approaching 4 cm.
- Explicit acknowledgement in the note and to the patient that growth kinetics are an imperfect surrogate - some aggressive tumors are indolent-appearing - and that delayed intervention appears safe in selected series but rests on observational data.
- Clear criteria given in advance, so the decision to treat is not renegotiated at each scan.